Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-၀.၂၁%
၁,၀၉၁.၅၁
-၂.၃၀
-၀.၂၁%
—၁,၀၉၃.၈၁၁,၀၉၆.၅၂၁,၁၀၀.၂၂၁,၀၉၁.၅၁——
SIXC
Communications
SIXC
Communications
SIXC
+၀.၂၂%
၆၁၀.၁၁
+၁.၃၄
+၀.၂၂%
—၆၀၈.၇၇၆၀၈.၇၇၆၁၂.၉၇၆၀၈.၇၇——
SIXE
Energy
SIXE
Energy
SIXE
-၁.၃၄%
၁,၂၃၇.၉၈
-၁၆.၈၃
-၁.၃၄%
—၁,၂၅၄.၈၁၁,၂၅၃.၀၁၁,၂၅၃.၈၇၁,၂၂၆.၃၃——
SIXI
Industrials
SIXI
Industrials
SIXI
-၀.၉၃%
၁,၇၄၄.၇၁
-၁၆.၄၀
-၀.၉၃%
—၁,၇၆၁.၁၁၁,၇၆၄.၂၇၁,၇၆၆.၈၈၁,၇၄၄.၇၁——
SIXM
Financials
SIXM
Financials
SIXM
-၀.၃၇%
၆၄၀.၁၈
-၂.၄၀
-၀.၃၇%
—၆၄၂.၅၈၆၄၄.၈၇၆၄၈.၄၈၆၄၀.၁၈——
SIXR
Staples
SIXR
Staples
SIXR
-၀.၁၈%
၈၄၉.၅၈
-၁.၅၅
-၀.၁၈%
—၈၅၁.၁၃၈၅၅.၆၆၈၅၈.၇၅၈၄၅.၅၆——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-၀.၂၃%
၂၁၇.၄၈
-၀.၅၀
-၀.၂၃%
—၂၁၇.၉၈၂၁၇.၉၈၂၁၈.၆၅၂၁၆.၈၈——
SIXT
Technology
SIXT
Technology
SIXT
+၁.၅၂%
၃,၂၆၀.၆၉
+၄၈.၈၆
+၁.၅၂%
—၃,၂၁၁.၈၃၃,၂၂၇.၂၁၃,၂၆၈.၃၈၃,၂၂၆.၅၅——
SIXU
Utilities
SIXU
Utilities
SIXU
-၀.၆၉%
၉၄၂.၄၅
-၆.၅၃
-၀.၆၉%
—၉၄၈.၉၈၉၄၈.၅၈၉၅၇.၈၃၉၄၁.၉၇——
SIXV
Health care
SIXV
Health care
SIXV
-၀.၅၂%
၁,၄၆၆.၈၀
-၇.၇၂
-၀.၅၂%
—၁,၄၇၄.၅၂၁,၄၇၉.၀၃၁,၄၈၁.၀၄၁,၄၆၆.၈၀——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+၀.၂၂%
၂,၃၉၇.၅၀
+၅.၃၈
+၀.၂၂%
—၂,၃၉၂.၁၂၂,၃၉၆.၉၅၂,၄၂၁.၂၂၂,၃၈၂.၃၂——
CVM:NYSEAMERICAN
CEL-SCI Corp
၂.၂၈ US$
-၂၅.၇၃%
(-၀.၇၉) 1D
၂.၃၀ US$
+၀.၈၈% (+၀.၀၂၀)
After hours
Closed: မေ ၁, GMT-၄ ၁၆:၀၀:၀၀  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CVM...
Open
၂.၈၄ US$
High
၂.၉၀ US$
Low
၂.၂၅ US$
Mkt. cap
၁.၉၃ ကုဋေ
Volume
၈.၀၄ သိန်း
52-wk high
၁၃.၄၈ US$
52-wk low
၁.၉၈ US$
EPS
-၅.၂၄ US$
Beta
၀.၉၉
Shares outstanding
၈.၄၆ သန်း
No. of employees
၄၃
News stories
From sources across the web
Profile
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
About CEL-SCI Corp
CEO-
Employees၄၃
Foundedမတ် ၁၉၈၃
Headquartersဗီယင်နာ, ဗာဂျီးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitecel-sci.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
၂၀၂၅ မတ်
၂၀၂၅ ဇွန်
၂၀၂၅ စက်
၂၀၂၅ ဒီ
Revenue
-
-
-
-
Cost of goods sold
၄.၀၁ သန်း
၃.၇၄ သန်း
၃.၇၀ သန်း
၃.၆၈ သန်း
Cost of revenue
၄.၀၁ သန်း
၃.၇၄ သန်း
၃.၇၀ သန်း
၃.၆၈ သန်း
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၂.၃၈ သန်း
၁.၇၅ သန်း
၂.၃၃ သန်း
၁.၆၉ သန်း
Operating expense
၂.၃၈ သန်း
၁.၇၅ သန်း
၂.၃၃ သန်း
၁.၆၉ သန်း
Total operating expenses
၆.၃၉ သန်း
၅.၄၉ သန်း
၆.၀၃ သန်း
၅.၃၇ သန်း
Operating income
-၆.၃၉ သန်း
-၅.၄၉ သန်း
-၆.၀၃ သန်း
-၅.၃၇ သန်း
Other non operating income
-
-၃.၇၇ ထောင်
၆.၀၉ သောင်း
-
EBT including unusual items
-၆.၅၇ သန်း
-၅.၆၆ သန်း
-၆.၁၀ သန်း
-၅.၄၇ သန်း
EBT excluding unusual items
-၆.၅၇ သန်း
-၅.၆၆ သန်း
-၆.၁၀ သန်း
-၅.၄၆ သန်း
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၆.၅၇ သန်း
-၅.၆၆ သန်း
-၆.၁၀ သန်း
-၅.၄၇ သန်း
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-၁.၇၈ သိန်း
-၁.၇၂ သိန်း
-၁.၂၉ သိန်း
-၈.၇၈ သောင်း
Net interest expenses
-၁.၇၈ သိန်း
-၁.၇၂ သိန်း
-၁.၂၉ သိန်း
-၈.၇၈ သောင်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၅.၄၂ သန်း
-၄.၅၃ သန်း
-၅.၅၁ သန်း
-၄.၄၀ သန်း
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer